FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377016738> ?p ?o ?g. }

• W4377016738 endingPage "101993" @default.
• W4377016738 startingPage "101993" @default.
• W4377016738 abstract "BackgroundRadium-223, a targeted alpha therapy, is approved to treat bone-dominant metastatic castration-resistant prostate cancer (mCRPC), based on significantly prolonged overall survival versus placebo and a favourable safety profile in the phase 3 ALSYMPCA study. ALSYMPCA was conducted when few other treatment options were available, and prospectively collected data are limited on the use of radium-223 in the current mCRPC treatment landscape. We sought to understand long-term safety and treatment patterns in men who received radium-223 in real-world clinical practice.MethodsREASSURE (NCT02141438) is a global, prospective, observational study of radium-223 in men with mCRPC. Primary outcomes are adverse events (AEs), including treatment-emergent serious AEs (SAEs) and drug-related AEs during and ≤30 days after radium-223 completion, grade 3/4 haematological toxicities ≤6 months after last radium-223 dose, drug-related SAEs after radium-223 therapy completion, and second primary malignancies.FindingsData collection commenced on Aug 20, 2014, and the data cutoff date for this prespecified interim analysis was Mar 20, 2019 (median follow-up 11.5 months [interquartile range 6.0–18.6]), 1465 patients were evaluable. For second primary malignancies, 1470 patients were evaluable, 21 (1%) of whom had a total of 23 events. During radium-223 therapy, 311 (21%) of 1465 patients had treatment-emergent SAEs, and 510 (35%) had drug-related AEs. In the 6 months after completion of radium-223 therapy, 214 (15%) patients had grade 3/4 haematological toxicities. Eighty patients (5%) had post-treatment drug-related SAEs. Median overall survival was 15.6 months (95% confidence interval 14.6–16.5) from radium-223 initiation. Patient-reported pain scores declined or stabilised. Seventy (5%) patients had fractures.InterpretationREASSURE offers insight into radium-223 use in global real-world clinical practice with currently available therapies. At this interim analysis, with a median follow-up of almost 1 year, 1% of patients had second primary malignancies, and safety and overall survival findings were consistent with clinical trial experience. Final analysis of REASSURE is due in 2024.FundingBayer HealthCare." @default.
• W4377016738 created "2023-05-19" @default.
• W4377016738 creator A5000710774 @default.
• W4377016738 creator A5001591556 @default.
• W4377016738 creator A5004144764 @default.
• W4377016738 creator A5004503139 @default.
• W4377016738 creator A5004985848 @default.
• W4377016738 creator A5008633297 @default.
• W4377016738 creator A5020692060 @default.
• W4377016738 creator A5025405399 @default.
• W4377016738 creator A5044026528 @default.
• W4377016738 creator A5047408345 @default.
• W4377016738 creator A5050957629 @default.
• W4377016738 creator A5053749991 @default.
• W4377016738 creator A5065424304 @default.
• W4377016738 creator A5074756323 @default.
• W4377016738 creator A5088518998 @default.
• W4377016738 date "2023-06-01" @default.
• W4377016738 modified "2023-10-16" @default.
• W4377016738 title "Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer" @default.
• W4377016738 cites W1520607409 @default.
• W4377016738 cites W2141454098 @default.
• W4377016738 cites W2147376175 @default.
• W4377016738 cites W2149642768 @default.
• W4377016738 cites W2169557289 @default.
• W4377016738 cites W2283896427 @default.
• W4377016738 cites W2294907556 @default.
• W4377016738 cites W2320909684 @default.
• W4377016738 cites W2554704180 @default.
• W4377016738 cites W2565257802 @default.
• W4377016738 cites W2602989120 @default.
• W4377016738 cites W2735160137 @default.
• W4377016738 cites W2740382031 @default.
• W4377016738 cites W2800198416 @default.
• W4377016738 cites W2898122595 @default.
• W4377016738 cites W2909895382 @default.
• W4377016738 cites W2911490798 @default.
• W4377016738 cites W2913546854 @default.
• W4377016738 cites W2921609221 @default.
• W4377016738 cites W2925184412 @default.
• W4377016738 cites W2997471043 @default.
• W4377016738 cites W2999047517 @default.
• W4377016738 cites W3000713139 @default.
• W4377016738 cites W3032592962 @default.
• W4377016738 cites W3092344805 @default.
• W4377016738 cites W3166274652 @default.
• W4377016738 cites W3195077328 @default.
• W4377016738 doi "https://doi.org/10.1016/j.eclinm.2023.101993" @default.
• W4377016738 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37251627" @default.
• W4377016738 hasPublicationYear "2023" @default.
• W4377016738 type Work @default.
• W4377016738 citedByCount "2" @default.
• W4377016738 countsByYear W43770167382023 @default.
• W4377016738 crossrefType "journal-article" @default.
• W4377016738 hasAuthorship W4377016738A5000710774 @default.
• W4377016738 hasAuthorship W4377016738A5001591556 @default.
• W4377016738 hasAuthorship W4377016738A5004144764 @default.
• W4377016738 hasAuthorship W4377016738A5004503139 @default.
• W4377016738 hasAuthorship W4377016738A5004985848 @default.
• W4377016738 hasAuthorship W4377016738A5008633297 @default.
• W4377016738 hasAuthorship W4377016738A5020692060 @default.
• W4377016738 hasAuthorship W4377016738A5025405399 @default.
• W4377016738 hasAuthorship W4377016738A5044026528 @default.
• W4377016738 hasAuthorship W4377016738A5047408345 @default.
• W4377016738 hasAuthorship W4377016738A5050957629 @default.
• W4377016738 hasAuthorship W4377016738A5053749991 @default.
• W4377016738 hasAuthorship W4377016738A5065424304 @default.
• W4377016738 hasAuthorship W4377016738A5074756323 @default.
• W4377016738 hasAuthorship W4377016738A5088518998 @default.
• W4377016738 hasBestOaLocation W43770167381 @default.
• W4377016738 hasConcept C119060515 @default.
• W4377016738 hasConcept C121608353 @default.
• W4377016738 hasConcept C126322002 @default.
• W4377016738 hasConcept C141071460 @default.
• W4377016738 hasConcept C197934379 @default.
• W4377016738 hasConcept C23131810 @default.
• W4377016738 hasConcept C2777783956 @default.
• W4377016738 hasConcept C2777899217 @default.
• W4377016738 hasConcept C2780192828 @default.
• W4377016738 hasConcept C2780737065 @default.
• W4377016738 hasConcept C535046627 @default.
• W4377016738 hasConcept C61943457 @default.
• W4377016738 hasConcept C71924100 @default.
• W4377016738 hasConceptScore W4377016738C119060515 @default.
• W4377016738 hasConceptScore W4377016738C121608353 @default.
• W4377016738 hasConceptScore W4377016738C126322002 @default.
• W4377016738 hasConceptScore W4377016738C141071460 @default.
• W4377016738 hasConceptScore W4377016738C197934379 @default.
• W4377016738 hasConceptScore W4377016738C23131810 @default.
• W4377016738 hasConceptScore W4377016738C2777783956 @default.
• W4377016738 hasConceptScore W4377016738C2777899217 @default.
• W4377016738 hasConceptScore W4377016738C2780192828 @default.
• W4377016738 hasConceptScore W4377016738C2780737065 @default.
• W4377016738 hasConceptScore W4377016738C535046627 @default.
• W4377016738 hasConceptScore W4377016738C61943457 @default.
• W4377016738 hasConceptScore W4377016738C71924100 @default.
• W4377016738 hasLocation W43770167381 @default.
• W4377016738 hasLocation W43770167382 @default.

• next